Merck Sharp & Dohme China (MSD China)
This sponsor has funded 6 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 45840 | Ongoing | A multicenter, prospective, cohort study to investigate the incidence and clinical management of CMV infection in adult patients with hematological... | No | No |
| 47111 | Planned | Survey on Chinese urologists of BCG utilization in Chinese NMIBC patients | No | No |
| 48393 | Ongoing | China Real World Study on Patient Baseline Characteristics and Treatment Pattern of Endometrial Cancer (PEC) | No | No |
| 48396 | Ongoing | Clinicopathological feature and treatment pattern of esophageal cancers in China: the CHANNEL study | No | No |
| 48399 | Planned | A Prospectively Observational Study to Investigate the Epidemiology and Patient Profile of Chronic Cough in Chinese Respiratory Outpatient Department | No | No |
| 103485 | Planned | Assessment of Disease Feature and Treatment Pattern of Locally Advanced, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma in China... | No | No |
PAS by Risk Management Plan (RMP) requirement
Merck Sharp & Dohme China (MSD China)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Merck Sharp & Dohme China (MSD China)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Merck Sharp & Dohme China (MSD China)
1 Study countries specified are the following:
- China